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Abstract
Hepatocarcinoma is one of the most common lethal human malignant tumors, 
mainly because of active angiogenesis. This kind of high angiogenesis often 
accounts for early metastasis, rapid recurrence, and poor survival. Growing evi-
dence has proved that hepatocarcinoma angiogenesis is closely associated with 
multiple risk factors, such as DNA damages resulting from hepatitis B and C virus 
infection, aflatoxin B1 exposure, ethanol intake, and obesity. Genetic alterations 
and genomic instability, probably resulting from low DNA damage repair response 
(DRR) and the following unrepaired DNA lesions, are also increasingly recognized 
as important risk factors of hepatocarcinoma angiogenesis. Dysregulation of DRRs 
and signaling to cell cycle checkpoints involving in DRR pathways may accelerate 
the accumulation of DNA damages and trigger the dysregulation of angiogenesis-
related genes and the progression of hepatocarcinoma. In this review, we discussed 
DNA damages/DRRs and angiogenesis during hepatocarcinogenesis and their 
interactive regulations. Hopefully, the review will also remind the medical research-
ers and clinic doctors of further understanding and validating the values of DNA 
damages/DRRs in hepatocarcinoma angiogenesis.
Keywords: hepatocarcinoma, angiogenesis, DNA damage, DNA damage  
repair response
1. Introduction
Hepatocellular carcinoma, also termed as hepatocarcinoma, is one of the most 
common malignant tumors, with more than 500,000 new cases per year [1]. Until 
recently, it has been frequent to consider hepatocarcinoma as a tumor with low 
incidence in the western world but with high incidence in the eastern countries [1]. 
However, increasing data exhibit that the incidence of this tumor has increased in 
both western and eastern countries. Etiologically, several risk factors, including 
hepatitis B virus (HBV), hepatitis C virus (HCV), aflatoxin B1 (AFB1), and alcohol, 
have been identified for increasing disease incidence worldwide [2]. Although 
molecular mechanisms of hepatocarcinoma caused by these risk factors have not 
still been clear, chronic and permanent liver damage and damage response may 
play a vital role. Macrocosmically, liver damage consists of a series of pathologi-
cal changes, such as chronic hepatitis, liver cirrhosis, nodular hyperplasia, and 
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dysplasia [3]. Microcosmically, chronic DNA damage, including the formation of 
DNA adducts, DNA strand break and bulk, gene mutations, and genomic instabil-
ity, is the most important type [4].
Because of early blood metastasis and high death rate of this malignancy, it has 
become the third most common cause of cancer-associated deaths worldwide. This 
death risk could be explained by high angiogenesis capacities of hepatocarcinoma [1, 2]. 
Increasing evidence has exhibited that hepatocarcinoma patients with high microvessel 
density (MVD) in tumor tissues would feature a poor prognosis, and angiogenesis has 
been regarded as an important marker predicting the risk of invasiveness and metasta-
sis [5]. This chapter summarizes the latest findings in hepatocarcinoma angiogenesis, 
DNA damage, and damage repair response (DRR). We also try to shed light on the 
effects of DNA damage and dysregulation of DRR on tumor angiogenesis.
2. Angiogenesis and regulation in hepatocarcinoma
2.1 Angiogenesis process in hepatocarcinoma
Several previous reviews have summarized the angiogenesis in hepatocarcinoma 
[5–7]. In brief, angiogenesis is a kind of crucial biological function and survival 
potential for normal organism development, growth, and adaptation to new 
environment. The dynamic balance between increasing and decreasing potential of 
angiogenesis is essential in the different physiological and pathological conditions, 
such as injury cure, damage repair, inflammatory procession, tumor progression, 
blindness, and ischemia. Hepatocarcinoma angiogenesis was extensively studied 
via cell models, experimental animal models, and human tumor samples [5–7]. 
Accumulating data have proved that local hypoxia in tumor tissues and the change 
in genome resulting from genetic or environmental risk factors will lead to the 
secretion and synthetics of angiogenetic regulative factors and triggering angio-
genesis [8–10]. In hepatocarcinoma tissues, the process of angiogenesis consists of 
the following several stages: sprouting, extracellular matrix component (ECMs) 
reconstruction, endothelial cell (EC) migration and proliferation, lumen forma-
tion, and stabilization of newborn vessels (Figure 1) [11].
The establishment of conditions allowing ECs proliferation and migration, 
which often results from local hypoxia, first facilitates endothelial sprouting 
and budding. During this stage, hypoxia induces the secretion and synthetics of 
angiogenetic factors, such as nitric oxide (NO), vascular endothelial growth factor 
(VEGF), CD31, angiopoietin-1, and so on [11]. The NO-induced vasodilation and 
VEGF-caused high permeability result in the extravasation of plasma components 
(including fibrinogen and fibrin). Together with ECMs, these plasma components 
lay down and form provisional scaffolds for migrating ECs. The basement mem-
branes and ECMs (mainly consisting of collagen I and IV and laminin) are next 
degraded, and subsequently, ECs migrate into local sites and proliferate. Increasing 
proliferation of ECs in the local hypoxia tissues leads to the formation of nascent 
vessels with lumen. After that, nascent vessels are recruited and structurally 
stabilized under the conditions of physical forces and a series of molecules such as 
platelet-derived growth factor β (PDFG-β), angiopoietin-1, angiopoietin-2, VEGF, 
and transforming growth factor β1 (TGF-β1) [7, 11, 12].
Vessels in hepatocarcinoma differ from other liver diseases or normal vessels [5, 
11, 13]. First, tumor vessels typically appear as irregular diameter and abnormal 
branching patterns [5]. Second, pericytes of vessels are often incompletely covered 
or lost; furthermore, their basement membranes are also incomplete [11]. Third, 
tumor vessels sometimes form irregular channels and the walls of these channels are 
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comprised of cancer cells. Moreover, the endothelial cells may be replaced by cancer 
cells partially or completely. Finally, angiogenesis in hepatocarcinoma not only 
appears abnormal architecture but also accompanies abnormal molecular expres-
sion and regulation [6, 14]. These characteristics result in abnormal structures and 
function for hepatocarcinoma; however, they can provide some important cues for 
early diagnosis and therapeutic strategies for cases with hepatocarcinoma.
2.2 Angiogenesis regulation in hepatocarcinoma
A series of angiogenic and antiangiogenic factors (Tables 1 and 2) regulate the 
angiogenesis process in hepatocarcinoma [5]. During the process of hepatocarci-
noma angiogenesis, hypoxia and VEGF family play a vital role. Hypoxia in local 
Figure 1. 
Angiogenesis procession in hepatocarcinoma. The procession of angiogenesis consists of: (1) sprouting and 
budding; (2) ECM remodeling; (3) EC proliferation and migration; (4) lumen formation and three-D 
organization; and (5) stabilization of nascent vessels.
DNA Repair - An Update
4
No. Active factors Effects Process involved in 
hepatocarcinoma
AF01 NO Stimulating vasodilation Increasing vessel permeably
AF02 VEGF family 
members
(1) Increasing vascular permeability
(2) inducing EC proliferation
(3) Progressing leukocyte adhesion
(4) Regulating neovascular lumen 
diameter
(1) Sprouting and budding
(2) Vessel growth 3-D 
organization
AF03 VEGF-R Integrate angiogenic and survival 
signals
Vessel growth
AF04 NRP-1 Integrate angiogenic and survival 
signals
Vessel growth
Angiopoietins Inducing EC proliferation Vessel growth
IL-4 Inducing EC proliferation Vessel growth
IL-8 Inducing EC proliferation Vessel growth
Hepatocyte growth 
factor
Inducing EC proliferation Vessel growth
Tissue factor Inducing EC proliferation Vessel growth
Fibronectin Progressing ECM remodeling
AF05 Integrins avb3 (1) ECM receptors, intercellular 
communication
(2) Mobilized during EC migration
(3) Regulating neovascular lumen 
diameter
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF06 Integrins avb5 (1) ECM receptors, intercellular 
communication
(2) Mobilized during EC migration
(3) Regulating neovascular lumen 
diameter
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF07 Integrins a6b1 (1) ECM receptors, intercellular 
communication
(2) Mobilized during EC migration
(3) Regulating neovascular lumen 
diameter
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF08 uPA (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF09 Plasminogen 
activators
(1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF10 MMPs (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF11 Heparinases (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF12 chymases (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF13 Tryptases (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
AF14 Cathepsins (1) Remodeling ECM
(2) Releasing and activating growth 
factors
ECM remodeling and EC 
migration Newborn vessel 
stabilization
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No. Active factors Effects Process involved in 
hepatocarcinoma
AF15 PlGF Inducing EC proliferation Vessel growth
AF16 aFGF Inducing EC proliferation Vessel growth
AF17 bFGF Inducing EC proliferation Vessel growth
FGF-R1 Receptor for aFGF Vessel growth
FGF-R2 Receptor for bFGF Vessel growth
AF18 HGF Inducing EC proliferation Vessel growth
c-Met Receptor for HGF Vessel growth
AF19 TGF-a Inducing EC proliferation Vessel growth
AF20 TGF-b Inducing EC proliferation Vessel growth
EGF-R Receptor for TGF-a and TGF-b Vessel growth
AF21 MCP-1 and other 
chemokines
Pleiotropic role in angiogenesis Newborn vessel stabilization
AF22 MEF2C Regulating neovascular lumen 
diameter
Newborn vessel stabilization
AF23 Ephrin’s Determining branching and arterial/
venous specification
Newborn vessel stabilization
AF24 PDGF-B and 
receptors
Recruiting pericytes Newborn vessel stabilization
AF25 Ang-1 (1) Stabilizing intercellular contacts
(2) Inhibiting permeability
Newborn vessel stabilization
AF26 Ang-2 Ang-1 antagonist (destabilizes 
vessels; causes EC death)
Vessel regression
AF27 Tie-2 Receptor for Ang-1 and Ang-2 Newborn vessel stabilization
AF28 TGF- 1 (1) Promoting vessel maturation
(2) stimulating ECM generation
(3) Inducing differentiation of 
mesenchymal cells to pericytes
ECM remodeling and EC 
migration
AF29 Endoglin (1) Promoting vessel maturation
(2) stimulating ECM generation
(3) Inducing differentiation of 
mesenchymal cells to pericytes
ECM remodeling and EC 
migration
AF30 Cyr61 (1) Stimulating directed migration 
of EC through an AVB integrin-
dependent pathway
(2) Acting as ECM modifiers
(3) Promoting EC survival
ECM remodeling and EC 
migration
AF31 Fisp12 (1) Stimulating directed migration 
of EC through an AVB integrin-
dependent pathway
(2) Acting as ECM modifiers
(3) Promoting EC survival
ECM remodeling and EC 
migration
Abbreviations: VEGF, vascular endothelial growth factor; ECM, extracellular matrix component; EC, endothelial 
cell; PEDF, Pigment epithelium-derived factor; platelet and endothelial cell adhesion molecule 1; TIMPs, Tissue 
inhibitor of metalloproteases; IFN, interferon; MMPs, matrix metalloproteinases; Ang, angiopoietin; IL, interleukin; 
PIGF, placenta growth factor; HGF, hepatocyte growth factor; TGF, transforming growth factor; EGF, epidermal 
growth factor.
Table 1. 
Angiogenesis active regulative factors in hepatocarcinoma.
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No. Active factors Effects Process involved in 
hepatocarcinoma
IF01 Arrestin Suppressing VEGF-regulating 
vessel growth
Vessel growth
IF02 Canstatin (1) Interruption of stable cell-ECM 
connections
(2) Inducing EC apoptosis
Vessel regression
IF03 Interleukin 12 Suppressing EC cell proliferation Vessel growth
IF04 PEDF Suppressing EC cell proliferation Vessel growth
IF05 VE-cadherin (1) Adhering junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF06 PECAM-1 (1) Adhering junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF07 Plakoglobin (1) Adhering junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF08 b-Catenin (1) Adhering junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF09 Claudins (1) Tightening junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF10 Occludin (1) Tightening junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF11 JAM-1 (1) Tightening junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF12 JAM-2 (1) Tightening junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF13 JAM-3 (1) Tightening junction molecules
(2) Intercellular adhesion
(3) Providing vessel tightness
Newborn vessel 
stabilization
IF14 Connexins (1) Gap junction molecules
(2) Facilitating intercellular 
communication
Newborn vessel 
stabilization
IF15 Integrins avb3 Suppressing VEGF- and Flk-1-
mediated EC survival
Vessel growth
IF16 Integrins avb5 Suppressing VEGF- and Flk-1-
mediated EC survival
Vessel growth
IF17 PAI-1 (1) Inhibiting ECM degradation 
by MMPs (2) Inhibiting EC 
proliferation
ECM remodeling and 
EC migration
IF18 TIMPs (1) Inhibiting ECM degradation 
by MMPs (2) Inhibiting EC 
proliferation
ECM remodeling and 
EC migration
IF19 Angiostatin and related 
plasminogen fragments
Suppressing tumor angiogenesis Vessel growth
IF20 Endostatin Suppressing EC cell proliferation Vessel growth
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tumor tissues, an important pathophysiological phenomenon caused by rapid 
growth of tumor, leads to the expression of hypoxia-inducible factor (HIF)-1α, 
which is a key inducible factor for angiogenesis in hypoxia tissues [7, 14]. On the 
one hand, HIF-1α can induce the expression of hypoxia-response-related genes like 
NO, VEGF, transforming growth factor (TGF) α and β, adrenomedullin (ADM), 
LDL-receptor-related protein 1 (LRP1), and leptin; on the other hand, local 
hypoxia status in tumor tissues also downregulates the expression of antiangio-
genic factors such as thrombospondin-1 (TS1) and -2 (TS2) [15–17]. Additionally, 
growing literature has shown that lots of factors, including genetic or acquired 
alterations in the oncogenes (i.e., Ras, c-Jun, and Myc) and tumor suppressor genes 
(i.e., TP53), Hepatitis B Virus X (HBx) protein, chromobox 4, and DNA damage 
induced by chronic inflammation and AFB1 exposure, can increase the expres-
sion proangiogenic factors [18–23]. For example, HBx protein has a potential for 
increasing HIF-1α expression via promoting transcriptional and translational 
activity and therefore accelerating angiogenesis during carcinogenesis process of 
hepatocarcinoma [24]. Recent studies have reported that chromobox 4 (a known 
transcriptional regulator and also a SUMO E3 enzyme) can promote angiogenesis 
via stabilizing HIF-1 in hepatocarcinoma [18, 19]. VEGF (including its glycoprotein 
family members VEGF-A, -B, -C, and -D) is another important angiogenic factor 
that always upregulates in most cases with hepatocarcinoma [5]. The upregulation 
of VEGF in hepatocarcinoma is proved not only to increase tumor neovasculariza-
tion but also to accelerate tumor growth via in vitro cell experiments and animal 
No. Active factors Effects Process involved in 
hepatocarcinoma
IF21 Antithrombin III Suppressing EC cell proliferation Vessel growth
IF22 IFN-a Suppressing EC cell proliferation Vessel growth
IF23 IFN-b Suppressing EC cell proliferation Vessel growth
IF24 LIF Suppressing EC cell proliferation Vessel growth
IF25 PF4 Suppressing EC cell proliferation Vessel growth
IF26 TSP-1 Inhibiting lumen formation Vessel regression
IF27 Ang-1 (excess) Making vessels too tight and 
inhibiting sprouting
Newborn vessel 
stabilization
IF28 Ang-2 Facilitating sprouting in the 
presence of VEGF
Vessel regression
IF29 sTie-2 Inhibitor for Ang-1 and Ang-2 Vessel regression
IF30 sFlt-1 Inhibitor for VEGF family (1) Sprouting and 
budding
(2) Vessel growth 3-D 
organization
IF31 Thrombospondin-1 Suppressing EC cell proliferation Vessel growth
IF32 Thrombospondin-2 Suppressing EC cell proliferation Vessel growth
IF33 Tumstatin Suppressing EC cell proliferation Vessel growth
IF34 Vasostatin Suppressing EC cell proliferation Vessel growth
Abbreviations: VEGF, vascular endothelial growth factor; ECM, extracellular matrix component; EC, endothelial 
cell; PEDF, Pigment epithelium-derived factor; platelet and endothelial cell adhesion molecule 1; TIMPs, Tissue 
inhibitor of metalloproteases; IFN, interferon; MMPs, matrix metalloproteinases; Ang, angiopoietin.
Table 2. 
Angiogenesis inhibitive regulative factors in hepatocarcinoma.
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models. The role of VEGF is mediated mainly by two receptors: VEGF-R1 (also 
called Flt-1) and VEGF-R2 (also termed as KDR/Flk-1). Both VEGF-R1 and 
VEGF-R2 have tyrosine kinase activity and are normally expressed in hepatic 
parenchyma cells including endothelial cells of portal and sinusoidal tracts [5, 6]. In 
hepatocarcinoma, both mRNA and protein amount of them are increasing notice-
ably in the tumor tissues compared to peri-tumor tissues [25]. Some other factors, 
such as angiopoietin 1 and 2, involve in the regulation of angiogenesis in hepato-
carcinoma (Tables 1 and 2) [5, 6, 13]. Together, increasing angiogenic potential but 
decreasing antiangiogenic potential facilitates hepatocarcinoma angiogenesis.
2.3 Angiogenesis biomarkers in hepatocarcinoma
In the past decades, several biomarkers, such as VEGF, angiogenin, and MVD, 
have been selected for elucidating angiogenic potential of hepatocarcinoma. Table 3  
summarized the potential of these biomarkers for hepatocarcinoma angiogenesis 
and angiogenesis-related tumor biological actions. Among these biomarkers, VEGF 
is concerned especially because of its clinic significance. For example, a hospital-
based clinic samples analyses (including 7 cases with liver low-grade dysplastic nod-
ule [DN], 8 cases with liver high-grade DN, 11 cases with early hepatocarcinoma, 17 
cases with small hepatocarcinoma, and 21 cases with advanced hepatocarcinoma) 
by Park et al. [26] showed that the amount of VEGF increased gradually from 
low-grade DN to early hepatocarcinoma. Furthermore, this increasing expression 
of VEGF is significantly associated with neoangiogenesis (marked by MVD with 
CD34 staining) and cancer cell proliferation. Collectively, we can conclude that 
increasing VEGF expression and MVD are positively associated with tumor vascu-
larization and the following tumor progression and poor survival of tumor cases. 
Furthermore, increasing evidence has exhibited that serum levels of VEGF are not 
only parallel with the amount in tumor tissues but also can predict therapy response 
of patients with hepatocarcinoma [29–32]. Thus, VEGF may be useful for improv-
ing therapeutic strategies of hepatocarcinoma based on the angiogenesis thesis.
No. Study design Samples Results Ref#
1 Hospital-
based sample 
study
LGDs (n = 7), HGDs 
(n = 8), eHCCs 
(n = 11), shocks 
(n = 17), and aHCCs 
(n = 21)
(1) VEGF expression increases 
gradually from LGD to eHCC.
(2) The sHCCs has an increasing 
neoangiogenesis and cell proliferation 
compared to aHCCs.
(3) The levels of VEGF expression 
are positively associated with MVD 
(marked by CD34 staining).
[26]
2 Hospital-
based sample 
study
HCCs (n = 60) Amount of VEGF in the serum of 
patients positively correlates with that 
in the tumor tissues.
[27]
3 Hospital-
based sample 
study
HCs (n = 20), 
CHs (n = 36), LCs 
(n = 77), and HCCs 
(n = 86)
Plasm VEGF levels are increasing in 
patients with HCC compared to in 
non-HCCs and this increase will more 
noticeable in cases with metastasis HCCs.
[28]
4 Hospital-
based sample 
study
HCs (n = 30), LCs 
(n = 26), and HCCs 
(n = 52)
Plasm VEGF levels are increasing in 
patients with HCC compared to in non-
HCCs and this increase will shorten the 
survival of HCCs.
[29]
5 Prospective 
study
HCCs (n = 100) Plasm VEGF levels of HCC cases are 
related to tumor stage, postoperation 
recurrence, and blood invasion.
[30]
9Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
3. DNA damage and DRR in hepatocarcinoma
3.1 DNA damage induced by risk factors for hepatocarcinoma
Multiple risk factors, including HBV and HCV infection, AFB1 exposure, 
ethanol consumption, and obesity, have been reported to correlate with hepa-
tocarcinogenesis (Figure 2) [4]. These risk factors can induce multiple types of 
DNA damage, such as DNA single-stand break (SSB), double-strand break (DSB), 
base damage, DNA-adduct formation, oxidation damage, gene mutation, chromo-
somal aberration, and genomic instability [4]. Results from epidemiological and 
experimental studies show that viral-DNA damage relationship is characterized by: 
No. Study design Samples Results Ref#
6 Hospital-
based sample 
study
HC (n = 15) and 
HCCs (n = 98)
Serum VEGF is a significant biomarker 
for HCC survival (including OS and 
RFS).
[31]
7 Prospective 
study
HCCs (n = 80) Serum VEGF levels were correlated 
with clinical data, tumor response to 
TACE and survival results.
[32]
8 Hospital-
based sample 
study
HCCs (n = 48) TACE treatment can upregulate 
expression and bFGF in HCC tissues 
possibly due to hypoxia and ischemia.
[33]
9 Hospital-
based sample 
study
HCCs (n = 38) TACE treatment can upregulate 
expression and bFGF in HCC tissues 
possibly due to hypoxia and ischemia.
[34]
10 Hospital-
based sample 
study
HCCs (n = 41) Angiogenin mRNA in serum and tumor 
tissues positively associating with MVD 
and poor prognosis of cases
[35]
11 Hospital-
based sample 
study
HCCs (n = 90) MMP-2, MMP-9 and VEGF expression 
is positively correlated to the prognosis 
of HCC patients.
[36]
12 Hospital-
based sample 
study
HCCs (n = 30) The serum levels of Ang-2, HGF, IL-8, 
PDGF-BB, and VEGF were correlated 
with poor effects of sorafenib treatment 
in patients with HCC.
[37]
13 Hospital-
based sample 
study
CHs (n = 79) and 
HCCs (n = 89)
(1) TEMs are involved in HCC 
angiogenesis.
(2) The frequency of circulating TEMs 
was significantly higher in HCC than 
non-HCC patients.
(3) The TEMs have higher diagnostic 
value for HCC than AFP, PIVKA-II and 
ANG-2.
[38]
14 Animal model / Mobilized EPCs participate in tumor 
angiogenesis of HCC
[39]
Abbreviations: LGDs, patients with low-grade dysplasia; HGD, patients with high-grade dysplasia; eHCCs, patients 
with early hepatocellular carcinoma; HCC, hepatocellular carcinoma; sHCCs, patients with small HCC; aHCCs, 
patients with advanced HCC; HCCs, patients with HCC; HCs, healthy controls; LCs, patients with liver cirrhosis; 
VEGF, vascular endothelial growth factor; MVD, microvessel density; OS, overall survival; RFS, tumor reoccurrence-
free survival; TACE, transarterial chemoembolization; bFGF, basic fibroblast growth factor; EPCs, bone marrow-
derived endothelial progenitor cells; TEMs, TIE2-expressing monocytes/macrophages; Ang-2, angiopoietin-2; G-CSF, 
granulocyte colony-stimulating factor; HGF, hepatocyte growth factor; IL-8, interleukin-8.
Table 3. 
The potential of biomarkers for hepatocarcinoma angiogenesis and angiogenesis-related tumor biological 
actions.
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(1) the integration of viral gene (such as HBx gene) into the genome of liver cells 
and resulting genomic instability of host cells [21, 24, 40, 41]; (2) TP53 muta-
tion conducted by HBx integration resulting in abnormal cell response, including 
DNA repair, cell proliferation and cycle, and apoptosis potential [22]; (3) HCV 
core interfering the formation of Mre11/Rad50/Nbs1 (MRN) complex through 
the bind with Nbs1 [5]; (4) the inhibition of such DNA repair proteins as Ataxia 
telangiectasia mutated kinase (ATM) [42, 43]; and (5) inducing dysregulation of 
signal pathways, including Wnt/β-catenin pathway, sex steroid pathway, p38MAPK 
pathway, PI3K/Akt pathway, transforming growth factor 𝛽 (TGF𝛽) pathway, 
NF-𝜅B pathway, and so on [11].
For AFB1-induced DNA damage, adducts formation and gene mutations are 
concerned especially [44]. AFB1 is a known I-type chemical hepatocarcinogen pro-
duced mainly by A. parasiticus and A. flavus and a suspected risk factor for hepato-
carcinoma in some dependent areas such as Sub-Saharan area, the southeast region 
of Asia, and the coast of southeast China. Results from prospective epidemiologi-
cal and animal studies have exhibited that AFB1-induced DNA damage plays a vital 
role in the process of hepatocarcinoma caused by AFB1 exposure [40, 45]. Studies 
of AFB1 metabolism have further proved that cytochrome P450 (CYP) enzymes 
Figure 2. 
Risk factors-induced DNA damage and damage repair response during hepatocarcinoma. Abbreviations: 
HBV, hepatitis B virus; HCV, hepatitis C virus; AFB1, aflatoxin B1; AFBO, AFB1-8,9-epoxide; IL, 
interleukin; TGF, transforming growth factor.
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in hepatocytes can facilitate AFB1 into its epoxy compound, also termed as AFB1-
8,9-epoxide (AFBe). AFBe can covalently bind to genomic DNA and ultimately 
induce multiple types of DNA damage [46, 47]. Increasing evidence exhibits 
that AFB1 can multiplicatively interact with HBV and/or HCV infection during 
hepatocarcinogenesis, and that, this multiplicative interaction may be associated 
with more noticeable DNA damage induced by both AFB1 exposure and HBV/
HCV infection [23]. Epidemiological studies based on the case-control design with 
a large sample have proved that patients with chronic virus hepatitis (including B 
and C type) will feature increasing hepatocarcinoma risk under the conditions of 
high AFB1 exposure [46]. Furthermore, patients with high AFB1 often companies 
with chronic virus infection and faces higher frequency of gene mutation like TP53 
and ras [47]. Interestingly, the mutation at the codon 249 of TP53 gene, namely 
G:C > T:A mutation resulting in the change of arginine to serine, has been identi-
fied as a relatively specifically change and named AFB1-induced hot-spot mutation 
[44]. This mutation may lead to the dysfunction of TP53 protein and abnormal 
cell actions like promoting cell growth, inhibiting cell apoptosis, and inhibiting 
transcription mediated by TP53 [40].
Other risk factors like alcohol intake also cause malignant transformation 
of hepatocytes. Chronic ethanol intake will significantly increase hepatocar-
cinoma risk (about five times) if more than 80 g/day × 10 years. Actually, less 
than this amount of uptake also increases cancer risk in spite of nonsignificance 
[48]. Although mechanisms are not still clear, increasing data have shown that 
chronic hepatic injury, abnormal regeneration, and cirrhosis may act some 
role in hepatocarcinogenesis [4]. Pathological and molecular biological studies 
display that acetaldehyde, an important metabolic product of ethanol, can bind 
to DNA and form DNA adducts. The DNA adduct formation caused could trigger 
replication errors and/or mutations in tumor suppressor genes and/or oncogene 
[4]. Additionally, oxidative DNA damage is more noticeable in tissues with 
hepatocarcinoma than peri-tumor tissues [40, 46]. However, it is unclear whether 
acetaldehyde-DNA adducts and oxidative damages are true carcinogens and how 
they trigger hepatocarcinogenesis [4, 49]. Therefore, future studies on DNA 
damage are needed to better validate these risk factors and detailed molecular 
mechanisms.
3.2 DRR in hepatocarcinoma
DNA damage will trigger DRR pathways, a kind of prompt signal event which 
can harmonize whether cells obtain cycle arrest for DNA repair or induce death 
for eliminating cells with severe DNA damage and genomic instability [4]. In 
human, cells develop several types of surveillance mechanisms consisting of SSB 
repair (SSBR), DSB repair (DSBR), base excision repair (BER), base mismatch 
repair (MMR), and nucleotide excision repair (NER) (Figure 2) [4, 40]. Among 
these DNA repair pathways, BER, MMR, and NER can repair base damage such 
as base mismatches, AFB1-DNA adducts, DNA pyrimidine dimers, and DNA 
damage induced by irradiation and anticancer drugs. SSBR can repair SSB that 
is a severe DNA damage, if not repaired quickly, will disrupt genic transcription 
and replication and ultimately results in lethal DNA damage [40]. DSBR pathway 
involves in homologous recombination (HR), single-strand annealing (SSA), 
and nonhomologous end joining (NHEJ). HR pathway can repair DSBs through 
an accurate repair method using the undamaged homologous chromosome or 
sister-chromatid as DNA repair temple; whereas NHEJ and SSA pathways are 
nonhomologous repair methods and usually lead to essential mutagenesis, so far 
DNA Repair - An Update
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DRR 
pathway 
gene/
proteins
DRR 
pathway
Abnormal of DRR Effects on hepatocarcinoma Ref#
hOGG1 BER Ser to Cys at codon 326 Increased hepatocarcinoma risk [51]
XRCC1 BER and 
SSBR
Arg to His at codon 280 
Arg to Gln at codon 399 
Arg to Trp at codon 194
(1) Increasing individuals’ susceptibility to 
HBV infection
(2) Increasing individuals’ susceptibility to 
hepatocarcinoma
(3) Increasing amount of AFB1-DNA 
adducts in liver tissues
(4) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(5) Increasing the frequency of TP53M
(6) Increasing MVD
[52–56]
XRCC3 DSBR Thr to Met at codon 241 
rs1799796 A > G
(1) Increasing individuals’ susceptibility to 
hepatocarcinoma
(2) Increasing amount of AFB1-DNA 
adducts in liver tissues
(3) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(4) Increasing the frequency of TP53M
(5) Associating with hepatocarcinoma 
clinicopathological features
(6) Increasing MVD
[57–59]
XRCC4 DSBR rs28383151 G > A
Ala to Ser at codon 247
(1) Increasing individuals’ susceptibility to 
hepatocarcinoma
(2) Increasing amount of AFB1-DNA 
adducts in liver tissues
(3) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(4) Increasing the frequency of TP53M
(5) Associating with hepatocarcinoma 
clinicopathological features
(6) Increasing MVD
[20, 21, 
60–63]
XRCC5 DSBR rs16855458 C > A
rs9288516 T > A
XRCC5 expression
(1) Increasing individuals’ susceptibility to 
HBV infection
(2) Increasing individuals’ susceptibility to 
hepatocarcinoma
(3) Associating with biological actions of 
hepatocarcinoma cells, such as increasing 
XRCC5 expression inhibiting cancer cells 
proliferation
(4) Functioning as a tumor suppressor 
by inducing S-phase arrest in a TP53-
dependent pathway
[64–69]
XRCC6 DSBR XRCC6 expression (1) Increasing individuals’ susceptibility to 
hepatocarcinoma
(2) Decreasing Toll-like receptor 4 (TLR4) 
against hepatocarcinogenesis
(3) Increasing DNA damage, and 
promoting programmed cell death in 
TLR4-deficient livers
(4) Early diagnostic value for 
hepatocarcinoma
[70–73]
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DRR 
pathway 
gene/
proteins
DRR 
pathway
Abnormal of DRR Effects on hepatocarcinoma Ref#
XRCC7 DSBR rs7003908 T > G (1) Increasing individuals’ susceptibility to 
AFB1 exposure
(2) Increasing individuals’ susceptibility to 
hepatocarcinoma
(3) Increasing amount of AFB1-DNA 
adducts in liver tissues
(4) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(5) Increasing the frequency of TP53M
(6) Interacting with AFB1 exposure during 
hepatocarcinogenesis
(7) Increasing MVD
[21, 74, 75]
DNA-
PKcs
DSBR Amount in liver tissues Implying hepatocarcinoma-specificity [76]
TP53 DRR 
pathway
Genic mutations such 
as TP53M, Arg to His at 
codon 273, Arg to His at 
codon 175, Cys to Tyr at 
codon 135, and Arg to 
Trp at codon 248
1. Implying individuals’ AFB1 exposure
2. Associating with hepatocarcinoma risk
3. Increasing individuals’ susceptibility to 
hepatocarcinoma
4. Decreasing DRR potential and increas-
ing DNA damage
[40, 45, 
 77, 78]
XPC NER XPC expression
Lys to Gln at codon 939
(1) Increasing individuals’ susceptibility to 
hepatocarcinoma
(2) Increasing amount of AFB1-DNA 
adducts in liver tissues
(3) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(4) Increasing the frequency of TP53M and 
decreasing DRR potential
(5) Associating with hepatocarcinoma 
clinicopathological features
(6) Increasing XPC expression
(7) Increasing MVD
[21, 79–81]
XPD NER Lys to Gln at codon 751 (1) Increasing individuals’ susceptibility to 
hepatocarcinoma
(2) Increasing amount of AFB1-DNA 
adducts in liver tissues
(3) Increasing amount of adducts 
(including AFB1-DNA and AFB1-albumin 
adducts) in the peripheral WBCs
(4) Increasing the frequency of TP53M and 
decreasing DRR potential
(5) Interacting with gender during 
hepatocarcinoma
(6) Increasing MVD
[21, 82]
Rad50 NER Rad50 hook domain Strongly influencing Mre11 complex-
dependent DRR signaling, tissue 
homeostasis, and tumorigenesis
[83]
Nbs1 NER Rs1805794 C > G
Mutations in Nbs1
(1) Increasing hepatocarcinoma risk
(2) Associating with TP53 inactivation
[84–87]
PARP-1 BER DRR potential (1) Modifying biological actions of 
hepatocarcinoma cells
(2) A novel promising diagnostic marker 
for hepatocarcinoma
[88–90]
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as to induce chromosomal aberrations, abnormal cell cycle, and/or uncontrolled 
cell proliferation [50]. During DRR pathways, DNA repair genes play a central 
role [4]. Dysregulation of DRR caused by DNA repair genic mutations or low 
DNA repair capacity will increase hepatocarcinoma risk. Table 4 summarized 
the effects of abnormal DRR in hepatocarcinogenesis. This evidence shows that 
dysregulation of DRR resulting from mutations in DNA repair genes and corre-
sponding dysfunctions may promote hepatocarcinogenesis through the following 
pathways: (1) increasing individuals’ susceptibility to risk factors such as hepatitis 
virus infection and AFB1 exposure [40, 60, 101]; (2) increasing individuals’ 
susceptibility to cancer [45]; (3) increasing amount of carcinogens-DNA adducts 
in liver tissues [40]; (4) increasing amount of adducts (such as AFB1-DNA and 
AFB1-albumin adducts) in the peripheral WBCs and affecting immune reaction 
[61]; (5) increasing the frequency of tumor suppressor genes or oncogenes like 
Ras and TP53M [40, 47, 52, 61, 79]; and (6) interacting with risk factors during 
hepatocarcinogenesis [23]. Thus, the potential of DRR pathways should play an 
important function for hepatocarcinogenesis.
DRR 
pathway 
gene/
proteins
DRR 
pathway
Abnormal of DRR Effects on hepatocarcinoma Ref#
Rad10 NER rs11615 C > T
ERCC1–4533 G > A
ERCC1–8092 C > A
(1) Increasing hepatocarcinoma risk
(2) The amount of ERCC1 expression in 
tissues with hepatocarcinoma decreases 
cancer cells’ sensitivity on anti-cancer 
drugs
(3) Predicting the outcome of 
hepatocarcinoma patients receiving 
TACE treatment
[91–93]
ATM HR and 
ENEJ
Ser to Ala at codon 
1981
Ser to Ala at codon 
1893
Ser to Ala at codon 
367
Ser to Ala at codon 
2996
Autophosphorylation 
at codon 1981 Ser
(1) The functional deficiency in 
radioresistant DNA synthesis and 
substrate phosphorylation such as TP53, 
Chk2, Nbs1, and SMCI
(2) Increasing cells’ sensitivity to risk 
factors and risk factors-induced DNA 
damage such as adduct formation and 
chromosome aberrations
(3)The functional dysregulation for 
G2/M checkpoint
(4) Extending activations of DNA 
damage signaling pathways to reach S 
phase arrest in hepatocarcinoma cells
(5) Leading to ATM unable to be released 
from other ATM
molecules, and increasing gene mutation 
risk
[94–100]
Abbreviations: hOGG1, human oxoguanine glycosylase 1; XRCC1, X-ray repair cross complementing 1; BER, base 
excision repair; SSBR, single-strand break repair; HBV, hepatitis B virus; XRCC3, X-ray repair cross complementing 
3; AFB1, aflatoxin B1; DSBR, double-strand break repair; WBC, white blood cell; TP53M, hot-spot mutation at 
codon 249 of TP53 gene; DNA-PKcs, DNA-activated protein kinase catalytic subunit; XRCC4, X-ray repair cross 
complementing 4; XRCC5, X-ray repair cross complementing 5; XRCC6, X-ray repair cross complementing 6; XRCC7, 
X-ray repair cross complementing 7; XPC, xeroderma pigmentosum, complementation group C; XPD, xeroderma 
pigmentosum, complementation group D; NER, nucleotide excision repair; PARP-1, poly(ADP-ribose) polymerase 1; 
ATM, Ataxia telangiectasia mutated kinase.
Table 4. 
The association between abnormal DRR potential and hepatocarcinogenesis.
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4. Hepatocarcinoma angiogenesis induced by DRR
Risk factors induced DNA damages and dysregulated DRRs are regarded as 
molecular events [4]. In human, risk factors for hepatocarcinoma can manifest 
acute and chronic DNA damage. Acute and noticeable DNA damages often lead 
to severe chromosome aberration and even cell death, whereas chronic DNA 
damages are the earliest molecular change in hepatocytes and ultimately result in 
hepatocarcinoma [40]. In the past decades, angiogenesis induced by dysregula-
tion of DRR pathways may act as a vital role in the process of hepatocarcinoma. 
Evidence from epidemiological and clinicopathological studies has shown that 
higher potential of angiogenesis is in the liver of patients with chronic DNA 
damage and low DRR capacity [40, 102–105]. For example, Pastukh et al. [102] 
investigated the association between recruitment of DNA repair enzymes involv-
ing in BER pathway and VEGF expression via a chromatin immunoprecipitation 
technique. They found that hypoxia-induced reactive oxygen species (ROS) 
stress caused promoter base modifications targeted to hypoxic response elements 
(HREs) and increased VEGF expression. During this modification, 8-oxoguanine 
(8-oxodG, an oxidative DNA damage product) in VEGF promoter was temporally 
correlated with binding of human 8-oxodG glycosylase 1 (hOGG1, a BER repair 
enzyme), HIF-1α, redox effector factor-1, endonuclease one, and breaks in DNA 
strands. If 8-oxodG was decreased in the promoter region of VEGF, VEGF expres-
sion would downregulate [102]. Recent molecular epidemiological studies have 
further proved that genetic variants in hOGG1 genes increase hepatocarcinoma 
risk and modify the prognosis of this malignancy [103–105]. Collectively, these 
data suggest that increasing ROS like 8-oxodG resulting from low DRR capacity 
may promote angiogenesis.
Studies from high HBV and HCV infection and high AFB1 exposure area also 
display that the degrees of DNA damages are positively associated with MVD in 
tumor tissues from hepatocarcinoma [20, 55, 75, 79, 82]. For example, Lu et al. [20] 
investigated the effects of XRCC4 expression in tumor tissues on clinicopathologi-
cal features and prognosis of hepatocarcinoma and found that decreasing XRCC4 
expression was related to low DRR capacity, causing the formation of DNA adducts 
and TP53M. The dysregulation of XRCC4 may promote tumor proliferation and 
increase MVD. Several other studies further show that the low DRR capacity 
resulting from significant mutations in coding region of DNA repair genes (such as 
XRCC4, XRCC1, XPC, XPD, and XRCC7) increases MVD (Table 4) [21, 40, 52, 55, 
59, 61, 62, 79, 80, 82]. Results from Lu et al. [20] and our studies [61, 62] showed 
that genetic alterations in the coding regions of XRCC4 gene (including Ala to Ser 
at codon 247 and Thr to Ala at codon 56) can decrease levels of XRCC4 protein 
expression and cause increasing amount of AFB1-DNA adducts and mutative 
frequency of TP53 gene in tissues with hepatocarcinoma. They also found that the 
amount of AFB1-induced DNA adducts, including 8,9-dihydro-8-(N7-guanyl)-9-
hydroxy-AFB1 (AFB1-N7-Gua) and formamidopyridine AFB1 adduct (AFB1-FAPy), 
was positively associated with the number of microvessels (a biomarker for angio-
genesis). Results from our studies [79, 106, 107] furthermore displayed that three 
low DNA repair markers related to AFB1, including tumor risk, TP53M frequency, 
and AFB1-FAPy adduct amount, were significantly correlated with the number of 
microvessels in liver tissues. These individuals with high AFB1-FAPy adduct level 
in liver tissues had an increasing risk of high MVD than those low adduct level 
(OR = 1.68, 95% CI = 1.45–2.87) [106]. Liu et al. [108] and Wang et al. [109] further 
proved that the upregulation of microRNA-429 and microRNA-24 expression in 
tissues with hepatocarcinoma not only increased the amount of AFB1-DNA adducts 
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and the number of microvessels but also grew tumor metastasis risk via vessels 
and shorted patients’ survival. Recent evidence has shown that microRNA-24/
microRNA-429 can modify the capacity of DDR via controlling Nbs1 (a regula-
tor of DRR) [110, 111] and angiogenesis via regulating the crosstalk between the 
pro-contractile transforming growth factor-β/bone morphogenetic protein (TGF-β/
BMP) signal (inducing a quiescent ‘contractile’ phenotype) and the pro-synthetic 
platelet-derived growth factor (PDGF) signal (causing a proliferative ‘synthetic’ 
phenotype) [112, 113]. This suggests that microRNA-24/microRNA-429 may play an 
important regulative role between DRR capacity and angiogenesis. Taken together, 
this evidence proves that low DRR-induced MVD augmentation is regulated by the 
amount of DNA damage.
Evidence from in vitro and in vivo studies further shows that dysregulation of 
DRRs and signaling to cell cycle checkpoints (CCCs) may modify hepatocarcinoma 
angiogenesis. CCCs involving in DRRs mainly encompass G1/S and G2/M checkpoint 
[114]. During G1/S checkpoint, both ATR and ATM act as central activators for DRR 
via inducing the phosphorylation of p53 protein which can activate p21 (a Cdk inhibi-
tor). ATM/TP53/P21 pathway also plays an important function controlling G2/M 
procession [114]. The dysregulation of these factors and signal pathways can change 
the status of angiogenesis [115–119]. For example, Qin et al. [115] found that E2F1, 
an important cell cycle regulator, can modify angiogenesis via controlling VEGF 
expression by p53-dependent way. In this control model, deficient phenotype of E2F1 
will result in VEGF overexpression, while its positive phenotype decreases VEGF 
expression [115]. Factors controlling cell shape and cytosol can regulate the cycle of 
vessel endothelial cells and angiogenesis [116, 117]. In mice model with the deficiency 
of BCL-2 (an important regulatory factor in DDRs), cells featured increasing DNA 
damage [118]; the inhibition of BCL-2 will result in the arrest of cells in S phrase and 
suppression of tumor angiogenesis [119]. In an integrated genomic study (including 5 
hepatocarcinoma patients with hepatitis D visus [HDV] and 7 HDV-positive cirrhosis 
cases), Diaz et al. [120] investigated the association between HDV-related hepato-
carcinoma and potential signal pathways involved in DNA damage and repair and 
cell cycle and found significant interactions of DDR/cell cycle-related genes, such as 
BRCA1, BARD1, CDK1, CDKN2C, CCNA2, CCNB1, CCNE2, GSK3B, H2AFX, MSH2, 
NPM1, PRKDC, and TOP2A. Results from the t-SNP (t-distributed stochastic neigh-
bor embedding analyses) further exhibited that HUS1, BRCA1, BARD1, GADD45, 
DNA-damage-induced 14-3-3σ, and MSH2 gene involving in DRRs valuably scored 
with regulatory genes (such as ATM, TP53, NO, and epidermal growth factor), which 
involve in G2/M checkpoint and angiogenesis [120]. The dysregulation of HUS1 
and corresponding genotoxin-activated checkpoint complex (also termed as Rad9-
Rad1-Hus1complex) will cause abnormal DRR capacity and cell cycle in response 
to DNA damage and promote the alteration of hematogenous metastatic phenotype 
for hepatocarcinoma [121, 122]. The genetic alterations and abnormal expression of 
BRCA1 and GADD45 (two important regulatory factors in DRR and apoptosis path-
ways) in hepatocytes can also change TP53-dependent CCCs and VEGF expression 
[123, 124]. Altogether, these studies have proved that the dysregulation of DDRs can 
cause the abnormal regulation of CCCs and change the status of hepatocarcinoma 
angiogenesis.
Detailed molecular mechanisms of DRR dysregulation promoting hepatocarci-
noma angiogenesis have still not been fully understood. Several possible pathways 
may play some important roles. First, DNA damage agents induce NO synthase 
and increase the expression of VEGF and HGF [125, 126]. Second, DNA damage 
agents like AFB1 cause the mutations of such genes as TP53, ras, and DNA repair 
genes. Activation of oncogenes and inactivation of tumor suppression genes and 
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DNA repair genes lead to uncontrolled expression of genes involving in angiogen-
esis such as VEGF and Ang-1/2 [5, 6]. Third, genetic alterations in DRR pathways 
may alter the microenvironment of tumor and promote angiogenesis [127–129]. 
Fourth, the abnormal DRRs may accelerate the accumulation of DNA damages 
and trigger the dysregulation of angiogenesis-related genes and the progression of 
hepatocarcinoma. Finally, some metabolic products (such as AFBO) or nucleotide 
sequences (HBx) of DNA agents can bind to genomic DNA of hepatocytes and 
may increase the activation of VEGF HREs [22, 40, 41, 45]. Taken together, under 
the conditions of low DRR capacity and/or chronic risk factors, DNA damages will 
accumulate in hepatocytes and ultimately induce hepatocarcinogenesis and tumor 
angiogenesis.
5. Summary and further direction
Abnormal angiogenesis and DNA damages/DRRs are two important pathophysi-
ological events in the process of hepatocarcinogenesis. Recently, it has become a 
growing evidence of DNA damage and repair and angiogenesis in hepatocarcino-
genesis. Low DRR capacity resulting genetic or obtained alterations may lead to the 
accumulation of DNA damages and induce angiogenesis and ultimately promote 
hepatocarcinoma development. The main challenge for this field is the explana-
tions of molecular basis and regulative signal pathways of DNA damages/DRRs 
interacting with angiogenesis during hepatocarcinogenesis. A better understanding 
of hypervascular feature and corresponding mechanisms of hepatocarcinoma on 
the basis of DNA damage/DRR pathway may be helpful for the medical researchers 
and clinic doctors exploring and validating hepatocarcinogenesis but also for them 
designing safe and efficient antiangiogenic drugs.
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Abbreviations
AFB1 aflatoxin B1
Ang-2 angiopoietin-2
ATM ataxia telangiectasia mutated kinase
BER base excision repair
bFGF basic fibroblast growth factor
DNA-PKcs DNA-activated protein kinase catalytic subunit
DSBR double-strand break repair
DRR DNA damage repair response
G-CSF granulocyte colony-stimulating factor
HBV hepatitis B virus
HCV hepatitis C virus
MVD microvessel density
NER nucleotide excision repair
HGF hepatocyte growth factor
hOGG1 human oxoguanine glycosylase 1
IL-8 interleukin-8
PARP-1 poly(ADP-ribose) polymerase 1
SSBR single-strand break repair
TEMs TIE2-expressing monocytes/macrophages
TP53M hot-spot mutation at codon 249 of TP53 gene
VEGF vascular endothelial growth factor
XRCC1 X-ray repair cross complementing 1
XRCC3 X-ray repair cross complementing 3
XRCC4 X-ray repair cross complementing 4
XRCC5 X-ray repair cross complementing 5
XRCC6 X-ray repair cross complementing 6
XRCC7 X-ray repair cross complementing 7
XPC xeroderma pigmentosum, complementation group C
XPD xeroderma pigmentosum, complementation group D
19
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
Author details
Xi-Dai Long1,2,3*†, Zhou-Ximao Long4†, Xiao-Ying Huang2, Jin-Guang Yao2, 
Qiang Xia1 and Yan Deng5
1 Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao 
Tong University, Shanghai, China
2 Department of Pathology, The Affiliated Hospital of Youjiang Medical University 
for Nationalities, Baise, China
3 Guangxi Clinic Research Center of Hepatobiliary Diseases, Baise, China
4 Zhoupu Middle School, East China Normal University, Shanghai, China
5 Department of Epidemiology, Youjiang Medical University for Nationalities, 
Baise, China
*Address all correspondence to: sjtulongxd@263.net
† These authors contributed equally to this work
20
DNA Repair - An Update
[1] Torre LA, Bray F, Siegel RL, Ferlay J, 
Lortet-Tieulent J, Jemal A. Global cancer 
statistics, 2012. CA: A Cancer Journal 
for Clinicians. 2015;65:87-108. DOI: 
10.3322/caac.21262
[2] Blum HE, Spangenberg HC. 
Hepatocellular carcinoma: An 
update. Archives of Iranian Medicine. 
2007;10:361-371. DOI: 07103/AIM.0015
[3] Aravalli RN, Cressman EN, Steer 
CJ. Cellular and molecular mechanisms 
of hepatocellular carcinoma: An update. 
Archives of Toxicology. 2013;87:227-247. 
DOI: 10.1007/s00204-012-0931-2
[4] Yang SF, Chang CW, Wei RJ,  
Shiue YL, Wang SN, Yeh YT.  
Involvement of DNA damage 
response pathways in hepatocellular 
carcinoma. BioMed Research 
International. 2014;2014:153867. DOI: 
10.1155/2014/153867
[5] Semela D, Dufour JF. Angiogenesis 
and hepatocellular carcinoma. Journal 
of Hepatology. 2004;41:864-880. DOI: 
10.1016/j.jhep.2004.09.006
[6] Sun HC, Tang ZY. Angiogenesis 
in hepatocellular carcinoma: The 
retrospectives and perspectives. 
Journal of Cancer Research and Clinical 
Oncology. 2004;130:307-319. DOI: 
10.1007/s00432-003-0530-y
[7] Sugimachi K, Tanaka S, Terashi T, 
Taguchi K, Rikimaru T, Sugimachi K. 
The mechanisms of angiogenesis in 
hepatocellular carcinoma: Angiogenic 
switch during tumor progression. 
Surgery. 2002;131:S135-S141. DOI: 
10.1067/msy.2002.119365
[8] Machado MV, Janeiro A, 
Miltenberger-Miltenyi G, Cortez-
Pinto H. Genetic polymorphisms of 
proangiogenic factors seem to favor 
hepatocellular carcinoma development 
in alcoholic cirrhosis. European Journal 
of Gastroenterology & Hepatology. 
2014;26:438-443. DOI: 10.1097/
MEG.0000000000000044
[9] He Y, Ni J, Chen S, Jiang Y, Jia 
S, Gao Y. The vascular endothelial 
growth factor-2549 insertion/deletion 
polymorphism is not associated 
with susceptibility to hepatocellular 
carcinoma in Chinese. DNA and Cell 
Biology. 2010;29:393-396. DOI: 10.1089/
dna.2009.1015
[10] Kong SY, Park JW, Lee JA, Park JE, 
Park KW, Hong EK, et al. Association 
between vascular endothelial growth 
factor gene polymorphisms and survival 
in hepatocellular carcinoma patients. 
Hepatology. 2007;46:446-455. DOI: 
10.1002/hep.21720
[11] Chaparro M, Sanz-Cameno P, 
Trapero-Marugan M, Garcia-Buey L,  
Moreno-Otero R. Mechanisms of 
angiogenesis in chronic inflammatory 
liver disease. Annals of Hepatology. 
2007;6:208-213. DOI: PMID18007549
[12] Wietecha MS, Cerny WL, 
DiPietro LA. Mechanisms of vessel 
regression: Toward an understanding 
of the resolution of angiogenesis. 
Current Topics in Microbiology and 
Immunology. 2013;367:3-32. DOI: 
10.1007/82_2012_287
[13] Medina J, Arroyo AG, 
Sanchez-Madrid F, Moreno-
Otero R. Angiogenesis in chronic 
inflammatory liver disease. Hepatology. 
2004;39:1185-1195. DOI: 10.1002/
hep.20193
[14] Kim KR, Moon HE, Kim 
KW. Hypoxia-induced angiogenesis 
in human hepatocellular carcinoma. 
Journal of Molecular Medicine (Berlin, 
Germany). 2002;80:703-714. DOI: 
10.1007/s00109-002-0380-0
References
21
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
[15] Chiu DK, Tse AP, Xu IM, Di Cui J, 
Lai RK, Li LL, et al. Hypoxia inducible 
factor HIF-1 promotes myeloid-derived 
suppressor cells accumulation through 
ENTPD2/CD39L1 in hepatocellular 
carcinoma. Nature Communications. 
2017;8:517. DOI: 10.1038/
s41467-017-00530-7
[16] Mandl M, Depping R. ARNT is 
a potential direct HIF-1 target gene 
in human Hep3B hepatocellular 
carcinoma cells. Cancer Cell 
International. 2017;17:77. DOI: 10.1186/
s12935-017-0446-2
[17] Shneor D, Folberg R, Pe'er J, 
Honigman A, Frenkel S. Stable 
knockdown of CREB, HIF-1 and HIF-2 
by replication-competent retroviruses 
abrogates the responses to hypoxia in 
hepatocellular carcinoma. Cancer Gene 
Therapy. 2017;24:64-74. DOI: 10.1038/
cgt.2016.68
[18] Jiao HK, Xu Y, Li J, Wang W, 
Mei Z, Long XD, et al. Prognostic 
significance of Cbx4 expression 
and its beneficial effect for 
transarterial chemoembolization in 
hepatocellular carcinoma. Cell Death 
& Disease. 2015;6:e1689. DOI: 10.1038/
cddis.2015.57
[19] Li J, Xu Y, Long XD, Wang W, 
Jiao HK, Mei Z, et al. Cbx4 governs 
HIF-1alpha to potentiate angiogenesis 
of hepatocellular carcinoma by its 
SUMO E3 ligase activity. Cancer 
Cell. 2014;25:118-131. DOI: 10.1016/j.
ccr.2013.12.008
[20] Lu J, Wang XZ, Zhang TQ, Huang 
XY, Yao JG, Wang C, et al. Prognostic 
significance of XRCC4 expression in 
hepatocellular carcinoma. Oncotarget. 
2017;8:87955-87970. DOI: 10.18632/
oncotarget.21360
[21] Yao JG, Huang XY, Long XD.  
Interaction of DNA repair gene 
polymorphisms and aflatoxin B1 in 
the risk of hepatocellular carcinoma. 
International Journal of Clinical and 
Experimental Pathology. 2014;7:6231-
6244. DOI: PMC4203246
[22] Dewantoro O, Gani RA, Akbar 
N. Hepatocarcinogenesis in viral 
hepatitis B infection: The role of HBx 
and p53. Acta Medica Indonesiana. 
2006;38:154-159. DOI: PMID16953033
[23] Moudgil V, Redhu D, Dhanda S,  
Singh J. A review of molecular 
mechanisms in the development of 
hepatocellular carcinoma by aflatoxin 
and hepatitis B and C viruses. Journal of 
Environmental Pathology, Toxicology 
and Oncology. 2013;32:165-175. DOI: 
10.1615/JEnvironPatholToxicolOncol. 
2013007166
[24] Liu LP, Hu BG, Ye C, Ho RL, Chen 
GG, Lai PB. HBx mutants differentially 
affect the activation of hypoxia-
inducible factor-1alpha in hepatocellular 
carcinoma. British Journal of Cancer. 
2014;110:1066-1073. DOI: 10.1038/
bjc.2013.787
[25] O'Connor JP, Jayson GC. Do imaging 
biomarkers relate to outcome in patients 
treated with VEGF inhibitors? Clinical 
Cancer Research. 2012;18:6588-6598. 
DOI: 10.1158/1078-0432.CCR-12-1501
[26] Park YN, Kim YB, Yang KM, 
Park C. Increased expression of 
vascular endothelial growth factor 
and angiogenesis in the early stage 
of multistep hepatocarcinogenesis. 
Archives of Pathology & Laboratory 
Medicine. 2000;124:1061-1065. DOI: 
10.1043/0003-9985(2000)124<1061:IEO
VEG>2.0.CO;2
[27] Poon RT, Lau CP, Cheung ST, Yu 
WC, Fan ST. Quantitative correlation 
of serum levels and tumor expression 
of vascular endothelial growth factor in 
patients with hepatocellular carcinoma. 
Cancer Research. 2003;63:3121-3126. 
DOI: PMID12810638
[28] Jinno K, Tanimizu M, Hyodo I, 
Nishikawa Y, Hosokawa Y, Doi T, 
DNA Repair - An Update
22
et al. Circulating vascular endothelial 
growth factor (VEGF) is a possible 
tumor marker for metastasis in human 
hepatocellular carcinoma. Journal of 
Gastroenterology. 1998;33:376-382. 
DOI: PMID9658317
[29] Kim SJ, Choi IK, Park KH, Yoon SY, 
Oh SC, Seo JH, et al. Serum vascular 
endothelial growth factor per platelet 
count in hepatocellular carcinoma: 
Correlations with clinical parameters 
and survival. Japanese Journal of 
Clinical Oncology. 2004;34:184-190. 
DOI: PMID15121753
[30] Poon RT, Ng IO, Lau C, Zhu LX, 
Yu WC, Lo CM, et al. Serum vascular 
endothelial growth factor predicts 
venous invasion in hepatocellular 
carcinoma: A prospective study. Annals 
of Surgery. 2001;233:227-235. DOI: 
PMC1421205
[31] Chao Y, Li CP, Chau GY, Chen CP, 
King KL, Lui WY, et al. Prognostic 
significance of vascular endothelial 
growth factor, basic fibroblast growth 
factor, and angiogenin in patients with 
resectable hepatocellular carcinoma 
after surgery. Annals of Surgical 
Oncology. 2003;10:355-362. DOI: 
10.1245/ASO.2003.10.002
[32] Poon RT, Lau C, Yu WC, Fan 
ST, Wong J. High serum levels of 
vascular endothelial growth factor 
predict poor response to transarterial 
chemoembolization in hepatocellular 
carcinoma: A prospective study. 
Oncology Reports. 2004;11:1077-1084. 
DOI: 10.3892/or.11.5.1077
[33] Liao X, Yi J, Li X, Yang Z, 
Deng W, Tian G. Expression of 
angiogenic factors in hepatocellular 
carcinoma after transcatheter arterial 
chemoembolization. Journal of 
Huazhong University of Science 
and Technology. Medical Sciences. 
2003;23:280-282. DOI: PMID14526434
[34] Suzuki H, Mori M, Kawaguchi C,  
Adachi M, Miura S, Ishii H. Serum 
vascular endothelial growth factor in 
the course of transcatheter arterial 
embolization of hepatocellular 
carcinoma. International Journal of 
Oncology. 1999;14:1087-1090. DOI: 
10.3892/ijo.14.6.1087
[35] Hisai H, Kato J, Kobune M, 
Murakami T, Miyanishi K, Takahashi 
M, et al. Increased expression of 
angiogenin in hepatocellular carcinoma 
in correlation with tumor vascularity. 
Clinical Cancer Research. 2003;9: 
4852-4859. DOI: PMID14581357
[36] Guo RP, Zhong C, Shi M, Zhang 
CQ , Wei W, Zhang YQ, et al. Clinical 
value of apoptosis and angiogenesis 
factors in estimating the prognosis of 
hepatocellular carcinoma. Journal of 
Cancer Research and Clinical Oncology. 
2006;132:547-555. DOI: 10.1007/
s00432-006-0097-5
[37] Miyahara K, Nouso K, Tomoda T, 
Kobayashi S, Hagihara H, Kuwaki K, 
et al. Predicting the treatment effect 
of sorafenib using serum angiogenesis 
markers in patients with hepatocellular 
carcinoma. Journal of Gastroenterology 
and Hepatology. 2011;26:1604-1611. 
DOI: 10.1111/j.1440-1746.2011.06887.x
[38] Matsubara T, Kanto T, Kuroda S, 
Yoshio S, Higashitani K, Kakita N, 
et al. TIE2-expressing monocytes as a 
diagnostic marker for hepatocellular 
carcinoma correlates with angiogenesis. 
Hepatology. 2013;57:1416-1425. DOI: 
10.1002/hep.25965
[39] Sun XT, Yuan XW, Zhu HT, Deng 
ZM, Yu DC, Zhou X, et al. Endothelial 
precursor cells promote angiogenesis in 
hepatocellular carcinoma. World Journal 
of Gastroenterology. 2012;18:4925-4933. 
DOI: 10.3748/wjg.v18.i35.4925
[40] Long XD, Yao JD, Yang Q, 
Huang CH, Liao P, Nong LG, et al. 
Polymorphisms of DNA repair genes 
and toxicological effects of aflatoxin 
B1 exposure. In: Faulkner AG, editor. 
23
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
Aflatoxins: Food Sources, Occurrence 
and Toxicological Effects. 1. New York: 
Nova Science Publishers; 2014. pp. 125-
156. DOI: 978-1-63117-298-4
[41] Niller HH, Ay E, Banati F, 
Demcsak A, Takacs M, Minarovits J. 
Wild type HBx and truncated HBx: 
Pleiotropic regulators driving sequential 
genetic and epigenetic steps of 
hepatocarcinogenesis and progression 
of HBV-associated neoplasms. Reviews 
in Medical Virology. 2016;26:57-73. DOI: 
10.1002/rmv.1864
[42] Huang CY, Hsieh FS, Wang CY, 
Chen LJ, Chang SS, Tsai MH, et al. 
Palbociclib enhances radiosensitivity 
of hepatocellular carcinoma and 
cholangiocarcinoma via inhibiting 
ataxia telangiectasia-mutated 
kinase-mediated DNA damage 
response. European Journal of Cancer. 
2018;102:10-22. DOI: 10.1016/j.
ejca.2018.07.010
[43] Min J, Guo K, Suryadevara PK, 
Zhu F, Holbrook G, Chen Y, et al. 
Optimization of a novel series of 
ataxia-telangiectasia mutated kinase 
inhibitors as potential radiosensitizing 
agents. Journal of Medicinal Chemistry. 
2016;59:559-577. DOI: 10.1021/acs.
jmedchem.5b01092
[44] Kew MC. Aflatoxins as a cause of 
hepatocellular carcinoma. Journal of 
Gastrointestinal and Liver Diseases. 
2013;22:305-310. DOI: PMID24078988
[45] Wu XM, Xi ZF, Lu J, Wang XZ, 
Zhang TQ, Huang XY, et al. Genetic 
single nucleotide polymorphisms 
(GSNPs) in the DNA repair genes 
and hepatocellular carcinoma related 
to aflatoxin B1 among Guangxiese 
population. In: Parine NR, editor. 
Genetic Polymorphisms. Vol. 1. Rijeka, 
Croatia: InTech; 2017. pp. 97-119. DOI: 
10.5772/intechopen.69530
[46] Kensler TW, Roebuck BD, Wogan 
GN, Groopman JD. Aflatoxin: A 
50-year odyssey of mechanistic and 
translational toxicology. Toxicological 
Sciences. 2011;120(Suppl 1):S28-S48. 
DOI: 10.1093/toxsci/kfq283
[47] Wang JS, Groopman JD. DNA 
damage by mycotoxins. Mutation 
Research. 1999;424:167-181. DOI: 
10.1016/S0027-5107(99)00017-2
[48] Kubo S, Kinoshita H, Hirohashi K, 
Tanaka H, Tsukamoto T, Shuto T, et al. 
High malignancy of hepatocellular 
carcinoma in alcoholic patients 
with hepatitis C virus. Surgery. 
1997;121:425-429. DOI: 10.1016/
S0039-6060(97)90313-5
[49] Leshets M, Silas YBH, Lehming N, 
Pines O. Fumarase: From the TCA cycle 
to DNA damage response and tumor 
suppression. Frontiers in Molecular 
Biosciences. 2018;5:68. DOI: 10.3389/
fmolb.2018.00068
[50] Davis AJ, Chen DJ. DNA double 
strand break repair via non-homologous 
end-joining. Translational Cancer 
Research. 2013;2:130-143. DOI: 
10.3978/j.issn.2218-676X.2013.04.02
[51] Piciocchi M, Cardin R, Cillo U, 
Vitale A, Cappon A, Mescoli C, et al. 
Differential timing of oxidative DNA 
damage and telomere shortening in 
hepatitis C and B virus-related liver 
carcinogenesis. Translational Research. 
2016;168:122-133. DOI: 10.1016/j.
trsl.2015.08.012
[52] Long XD, Ma Y, Huang HD, Yao JG, 
Qu DY, Lu YL. Polymorphism of XRCC1 
and the frequency of mutation in codon 
249 of the p53 gene in hepatocellular 
carcinoma among Guangxi population, 
China. Molecular Carcinogenesis. 
2008;47:295-300. DOI: 10.1002/
mc.20384
[53] Li LP, Wu W, Li XH, Song SS. The 
XRCC1 Arg280His gene polymorphism 
and hepatocellular carcinoma risk: A 
meta-analysis. Asian Pacific Journal of 
DNA Repair - An Update
24
Cancer Prevention. 2013;14:2033-2036. 
DOI: PMID23679314
[54] Li W, Yang F, Gui Y, Bian J. DNA 
repair gene XRCC1 Arg194Trp 
polymorphism and susceptibility to 
hepatocellular carcinoma: A meta-
analysis. Oncology Letters. 2014;8:1725-
1730. DOI: 10.3892/ol.2014.2351
[55] Long XD, Ma Y, Wei YP, Deng 
ZL. The polymorphisms of GSTM1, 
GSTT1, HYL1*2, and XRCC1, and 
aflatoxin B1-related hepatocellular 
carcinoma in Guangxi population, 
China. Hepatology Research. 
2006;36:48-55. DOI: 10.1016/j.
hepres.2006.06.004
[56] Zeng XY, Huang JM, Xu JW, Xu 
Y, Yu HP, Ji L, et al. Meta-analysis 
demonstrates lack of a relationship 
between XRCC1-399 gene 
polymorphisms and susceptibility to 
hepatocellular carcinoma. Genetics and 
Molecular Research. 2013;12:1916-1923. 
DOI: 10.4238/2013.March.15.5
[57] Avadanei ER, Giusca SE, Negura 
L, Caruntu ID. Single nucleotide 
polymorphisms of XRCC3 gene in 
hepatocellular carcinoma–relationship 
with clinicopathological features. Polish 
Journal of Pathology. 2018;69:73-81. 
DOI: 10.5114/pjp.2018.75340
[58] Ji RB, Qian YS, Hu AR, Hu 
YR. DNA repair gene XRCC3 T241M 
polymorphism and susceptibility to 
hepatocellular carcinoma in a Chinese 
population: A meta-analysis. Genetics 
and Molecular Research. 2015;14:15988-
15996. DOI: 10.4238/2015.December.7.11
[59] Long XD, Ma Y, Qu DY, Liu YG, 
Huang ZQ, Huang YZ, et al. The 
polymorphism of XRCC3 codon 241 and 
AFB1-related hepatocellular carcinoma 
in Guangxi population, China. Annals 
of Epidemiology. 2008;18:572-578. DOI: 
10.1016/j.annepidem.2008.03.003
[60] Makkoch J, Praianantathavorn K,  
Sopipong W, Chuaypen N, 
Tangkijvanich P, Payungporn S. Genetic 
Variations in XRCC4 (rs1805377) and 
ATF6 (rs2070150) are not associated 
with hepatocellular carcinoma in Thai 
patients with hepatitis B virus infection. 
Asian Pacific Journal of Cancer 
Prevention. 2016;17:591-595. DOI: 
PMID26925648
[61] Long XD, Zhao D, Wang C, 
Huang XY, Yao JG, Ma Y, et al. Genetic 
polymorphisms in DNA repair genes 
XRCC4 and XRCC5 and aflatoxin 
B1-related hepatocellular carcinoma. 
Epidemiology. 2013;24:671-681. DOI: 
10.1097/EDE.0b013e31829d2744
[62] Long XD, Yao JG, Zeng Z, 
Ma Y, Huang XY, Wei ZH, et al. 
Polymorphisms in the coding region of 
X-ray repair complementing group 4 
and aflatoxin B1-related hepatocellular 
carcinoma. Hepatology. 2013;58:171-
181. DOI: 10.1002/hep.26311
[63] Jung SW, Park NH, Shin JW, 
Park BR, Kim CJ, Lee JE, et al. 
Polymorphisms of DNA repair genes 
in Korean hepatocellular carcinoma 
patients with chronic hepatitis B: 
Possible implications on survival. 
Journal of Hepatology. 2012;57:621-627. 
DOI: 10.1016/j.jhep.2012.04.039
[64] Xu Y, Liu AJ, Gao YX, Hu MG, 
Zhao GD, Zhao ZM, et al. Expression of 
Ku86 and presence of Ku86 antibody as 
biomarkers of hepatitis B virus related 
hepatocellular carcinoma. Digestive 
Diseases and Sciences. 2014;59:614-622. 
DOI: 10.1007/s10620-013-2941-1
[65] Wang Z, Lin H, Hua F, Hu ZW.  
Repairing DNA damage by XRCC6/
KU70 reverses TLR4-deficiency-
worsened HCC development via 
restoring senescence and autophagic 
flux. Autophagy. 2013;9:925-927. DOI: 
10.4161/auto.24229
[66] Li R, Yang Y, An Y, Zhou Y, Liu Y, 
Yu Q, et al. Genetic polymorphisms in 
DNA double-strand break repair genes 
25
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
XRCC5, XRCC6 and susceptibility 
to hepatocellular carcinoma. 
Carcinogenesis. 2011;32:530-536. DOI: 
10.1093/carcin/bgr018
[67] Kim E, Li K, Lieu C, Tong S, Kawai 
S, Fukutomi T, et al. Expression of 
apolipoprotein C-IV is regulated by 
Ku antigen/peroxisome proliferator-
activated receptor gamma complex and 
correlates with liver steatosis. Journal 
of Hepatology. 2008;49:787-798. DOI: 
10.1016/j.jhep.2008.06.029
[68] Reliene R, Goad ME, Schiestl RH.  
Developmental cell death in the liver 
and newborn lethality of Ku86 deficient 
mice suppressed by antioxidant 
N-acetyl-cysteine. DNA Repair (Amst). 
2006;5:1392-1397. DOI: 10.1016/j.
dnarep.2006.06.007
[69] Muguruma M, Nishimura J, Jin M,  
Kashida Y, Moto M, Takahashi M,  
et al. Molecular pathological 
analysis for determining the possible 
mechanism of piperonyl butoxide-
induced hepatocarcinogenesis in mice. 
Toxicology. 2006;228:178-187. DOI: 
10.1016/j.tox.2006.08.029
[70] Chu L, Zhang X, Wang G, Zhou W, 
Du Z, Liu A, et al. Serum anti-Ku86: A 
potential biomarker for early detection 
of hepatocellular carcinoma. Zhonghua 
Zhong Liu Za Zhi. 2014;36:123-127. 
DOI: PMID24796461
[71] Wang Z, Yan J, Lin H, Hua F, Wang 
X, Liu H, et al. Toll-like receptor 4 
activity protects against hepatocellular 
tumorigenesis and progression by 
regulating expression of DNA repair 
protein Ku70 in mice. Hepatology. 
2013;57:1869-1881. DOI: 10.1002/
hep.26234
[72] Hsu CM, Yang MD, Chang WS, 
Jeng LB, Lee MH, Lu MC, et al. The 
contribution of XRCC6/Ku70 to 
hepatocellular carcinoma in Taiwan. 
Anticancer Research. 2013;33:529-535. 
DOI: PMID23393345
[73] Nomura F, Sogawa K, Noda K, 
Seimiya M, Matsushita K, Miura T, 
et al. Serum anti-Ku86 is a potential 
biomarker for early detection of 
hepatitis C virus-related hepatocellular 
carcinoma. Biochemical and 
Biophysical Research Communications. 
2012;421:837-843. DOI: 10.1016/j.
bbrc.2012.04.099
[74] Hsieh YH, Chang WS, Tsai CW, 
Tsai JP, Hsu CM, Jeng LB, et al. DNA 
double-strand break repair gene 
XRCC7 genotypes were associated 
with hepatocellular carcinoma risk in 
Taiwanese males and alcohol drinkers. 
Tumour Biology. 2015;36:4101-4106. 
DOI: 10.1007/s13277-014-2934-5
[75] Long XD, Yao JG, Huang YZ, 
Huang XY, Ban FZ, Yao LM, et al. DNA 
repair gene XRCC7 polymorphisms 
(rs#7003908 and rs#10109984) and 
hepatocellular carcinoma related 
to AFB1 exposure among Guangxi 
population, China. Hepatology 
Research. 2011;41:1085-1093. DOI: 
10.1111/j.1872-034X.2011.00866.x
[76] Pascale RM, Joseph C, Latte G, Evert 
M, Feo F, Calvisi DF. DNA-PKcs: A 
promising therapeutic target in human 
hepatocellular carcinoma? DNA Repair 
(Amst). 2016;47:12-20. DOI: 10.1016/j.
dnarep.2016.10.004
[77] Song H, Hollstein M, Xu Y. p53 
gain-of-function cancer mutants induce 
genetic instability by inactivating 
ATM. Nature Cell Biology. 2007;9:573-
580. DOI: 10.1038/ncb1571
[78] Dong P, Karaayvaz M, Jia N, 
Kaneuchi M, Hamada J, Watari H, et al. 
Mutant p53 gain-of-function induces 
epithelial-mesenchymal transition 
through modulation of the miR-130b-
ZEB1 axis. Oncogene. 2013;32:3286-
3295. DOI: 10.1038/onc.2012.334
[79] Long XD, Huang HD, Huang 
XY, Yao JG, Xia Q. XPC codon 939 
polymorphism is associated with 
DNA Repair - An Update
26
susceptibility to DNA damage induced 
by aflatoxin B1 exposure. International 
Journal of Clinical and Experimental 
Medicine. 2015;8:1197-1204. DOI: 
PMC4358568
[80] Long XD, Ma Y, Zhou YF, Ma AM, 
Fu GH. Polymorphism in xeroderma 
pigmentosum complementation group 
C codon 939 and aflatoxin B1-related 
hepatocellular carcinoma in the Guangxi 
population. Hepatology. 2010;52:1301-
1309. DOI: 10.1002/hep.23807
[81] Long XD, Ma Y, Huang YZ, Yi 
Y, Liang QX, Ma AM, et al. Genetic 
polymorphisms in DNA repair 
genes XPC, XPD, and XRCC4, and 
susceptibility to Helicobacter pylori 
infection-related gastric antrum 
adenocarcinoma in Guangxi population, 
China. Molecular Carcinogenesis. 
2010;49:611-618. DOI: 10.1002/
mc.20630
[82] Long XD, Ma Y, Zhou YF, Yao JG, 
Ban FZ, Huang YZ, et al. XPD Codon 
312 and 751 polymorphisms, and AFB1 
exposure, and hepatocellular carcinoma 
risk. BMC Cancer. 2009;9:400. DOI: 
10.1186/1471-2407-9-400
[83] Roset R, Inagaki A, Hohl M, Brenet 
F, Lafrance-Vanasse J, Lange J, et al. 
The Rad50 hook domain regulates DNA 
damage signaling and tumorigenesis. 
Genes & Development. 2014;28:451-
462. DOI: 10.1101/gad.236745.113
[84] Kim JH, Grosbart M, Anand R, 
Wyman C, Cejka P, Petrini JHJ. The 
Mre11-Nbs1 interface is essential 
for viability and tumor suppression. 
Cell Reports. 2017;18:496-507. DOI: 
10.1016/j.celrep.2016.12.035
[85] Wang Y, Li M, Long J, Shi XY, Li 
Q, Chen J, et al. Clinical significance 
of increased expression of Nijmegen 
breakage syndrome gene (NBS1) in 
human primary liver cancer. Hepatology 
International. 2014;8:250-259. DOI: 
10.1007/s12072-013-9500-x
[86] Wang Y, Hong Y, Li M, Long J, 
Zhao YP, Zhang JX, et al. Mutation 
inactivation of Nijmegen breakage 
syndrome gene (NBS1) in hepatocellular 
carcinoma and intrahepatic 
cholangiocarcinoma. PLoS One. 
2013;8:e82426. DOI: 10.1371/journal.
pone.0082426
[87] Huang MD, Chen XF, Xu G, 
Wu QQ, Zhang JH, Chen GF, et al. 
Genetic variation in the NBS1 gene is 
associated with hepatic cancer risk in 
a Chinese population. DNA and Cell 
Biology. 2012;31:678-682. DOI: 10.1089/
dna.2011.1421
[88] Li J, Dou D, Li P, Luo W, Lv W, 
Zhang C, et al. PARP-1 serves as a novel 
molecular marker for hepatocellular 
carcinoma in a Southern Chinese 
Zhuang population. Tumour Biology. 
2017;39:1010428317706914. DOI: 
10.1177/1010428317706914
[89] Mao X, Du S, Yang Z, Zhang L, Peng 
X, Jiang N, et al. Inhibitors of PARP-1 
exert inhibitory effects on the biological 
characteristics of hepatocellular 
carcinoma cells in vitro. Molecular 
Medicine Reports. 2017;16:208-214. 
DOI: 10.3892/mmr.2017.6568
[90] Luo Q, Li Y, Deng J, Zhang Z.  
PARP-1 inhibitor sensitizes arsenic 
trioxide in hepatocellular carcinoma 
cells via abrogation of G2/M checkpoint 
and suppression of DNA damage repair. 
Chemico-Biological Interactions. 
2015;226:12-22. DOI: 10.1016/j.
cbi.2014.12.007
[91] Chen L, Liu MM, Liu H, Lu D, Zhao 
XD, Yang XJ. ERCC1 and XRCC1 but not 
XPA single nucleotide polymorphisms 
correlate with response to chemotherapy 
in endometrial carcinoma. OncoTargets 
and Therapy. 2016;9:7019-7028. DOI: 
10.2147/OTT.S110976
[92] Hu ZJ, Xue JF, Zhang XY, Shi XS,  
Zhou H. Relationship between 
genetic polymorphism of ERCC1 
27
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
and susceptibility to liver cancer. 
Zhonghua Liu Xing Bing Xue Za Zhi. 
2010;31:1288-1291. DOI: 10.3760/cma.j.i
ssn.0254-6450.2010.11.020
[93] Li Y, Ou C, Shu H, Zhao H, Zhu B.  
The ERCC1-4533/8092, TNF-alpha 
238/308 polymorphisms and the risk of 
hepatocellular carcinoma in Guangxi 
Zhuang populations of China: Case-
control study. Medicine (Baltimore). 
2016;95:e5217. DOI: 10.1097/
MD.0000000000005217
[94] Liu J, Liu Y, Meng L, Ji B, Yang 
D. Synergistic antitumor effect of 
sorafenib in combination with ATM 
inhibitor in hepatocellular carcinoma 
cells. International Journal of Medical 
Sciences. 2017;14:523-529. DOI: 10.7150/
ijms.19033
[95] Ma CQ, Yang Y, Wang JM, Du GS, 
Shen Q, Liu Y, et al. The aPKCiota 
blocking agent ATM negatively 
regulates EMT and invasion of 
hepatocellular carcinoma. Cell Death 
& Disease. 2014;5:e1129. DOI: 10.1038/
cddis.2014.91
[96] Mansoori AA, Jain SK. Molecular 
links between alcohol and tobacco 
induced DNA damage, gene 
polymorphisms and patho-physiological 
consequences: A systematic review 
of hepatic carcinogenesis. Asian 
Pacific Journal of Cancer Prevention. 
2015;16:4803-4812. DOI: PMID26163595
[97] Gu DL, Chen YH, Shih JH, Lin CH, 
Jou YS, Chen CF. Target genes discovery 
through copy number alteration analysis 
in human hepatocellular carcinoma. 
World Journal of Gastroenterology. 
2013;19:8873-8879. DOI: 10.3748/wjg.
v19.i47.8873
[98] Huang S, Zhang Y, Zeng T. Effect 
of ATM-111 (G>A) polymorphism on 
cancer risk: A meta-analysis. Genetic 
Testing and Molecular Biomarkers. 
2016;20:359-366. DOI: 10.1089/
gtmb.2015.0320
[99] Vorechovsky I. Mutation analysis 
of large genomic regions in tumor 
DNA using single-strand conformation 
polymorphism. Lessons from the ATM 
gene. Methods in Molecular Medicine. 
2002;68:115-124. DOI: PMID11901497
[100] Thorstenson YR, Shen P, Tusher 
VG, Wayne TL, Davis RW, Chu G, et al. 
Global analysis of ATM polymorphism 
reveals significant functional constraint. 
American Journal of Human Genetics. 
2001;69:396-412. DOI: 10.1086/321296
[101] Yu L, Liu X, Han C, Lu S, Zhu G, 
Su H, et al. XRCC1 rs25487 genetic 
variant and TP53 mutation at codon 249 
predict clinical outcomes of hepatitis B 
virus-related hepatocellular carcinoma 
after hepatectomy: A cohort study for 10 
years' follow up. Hepatology Research. 
2016;46:765-774. DOI: 10.1111/
hepr.12611
[102] Pastukh V, Roberts JT, Clark DW, 
Bardwell GC, Patel M, Al-Mehdi AB, 
et al. An oxidative DNA "damage" and 
repair mechanism localized in the VEGF 
promoter is important for hypoxia-
induced VEGF mRNA expression. 
American Journal of Physiology. Lung 
Cellular and Molecular Physiology. 
2015;309:L1367-L1375. DOI: 10.1152/
ajplung.00236.2015
[103] Guo J, Yang J, Li Y. Association 
of hOGG1 Ser326Cys polymorphism 
with susceptibility to hepatocellular 
carcinoma. International Journal of 
Clinical and Experimental Medicine. 
2015;8:8977-8985. DOI: PMC4537974
[104] Sakamoto T, Higaki Y, Hara M, 
Ichiba M, Horita M, Mizuta T, et al. 
hOGG1 Ser326Cys polymorphism and 
risk of hepatocellular carcinoma among 
Japanese. Journal of Epidemiology. 
2006;16:233-239. DOI: 10.2188/
jea.16.233
[105] Wang W, Dang S, Li Y, Sun 
M, Jia X, Wang R, et al. hOGG1 
Ser326Cys polymorphism and risk of 
DNA Repair - An Update
28
hepatocellular carcinoma among East 
Asians: A meta-analysis. PLoS One. 
2013;8:e60178. DOI: 10.1371/journal.
pone.0060178
[106] Long XD, Yao JD, Yang Q, 
Huang CH, Liao P, Nong LG, et al. 
Polymorphisms of DNA repair genes 
and toxicological effects of aflatoxin 
B1 exposure. In: Faulkner AG, editor. 
Aflatoxins: Food Sources, Occurrence 
and Toxicological Effects. 1st ed. 
New York: Nova Science Publishers; 
2014. pp. 107-124
[107] Long XD, Huang HD, Xia Q. The 
polymorphism of XRCC3 codon 241 
and the hotspot mutation in the TP53 
gene in hepatocellular carcinoma 
induced by aflatoxin B1. Journal of 
Tumor. 2014;2:272-277. DOI: 10.6051/j.
issn.1819-6187.2014.02.57
[108] Liu YX, Long XD, Xi ZF, Ma Y, 
Huang XY, Yao JG, et al. MicroRNA-24 
modulates aflatoxin B1-related 
hepatocellular carcinoma prognosis 
and tumorigenesis. BioMed Research 
International. 2014;2014:482926. DOI: 
10.1155/2014/482926
[109] Huang XY, Yao JG, Huang HD,  
Wang C, Ma Y, Xia Q, et al. 
MicroRNA-429 modulates 
hepatocellular carcinoma 
prognosis and tumorigenesis. 
Gastroenterology Research and 
Practice. 2013;2013:804128. DOI: 
10.1155/2013/804128
[110] Lovric J, Mano M, Zentilin L,  
Eulalio A, Zacchigna S, Giacca M.  
Terminal differentiation of cardiac and 
skeletal myocytes induces permissivity 
to AAV transduction by relieving 
inhibition imposed by DNA damage 
response proteins. Molecular Therapy. 
2012;20:2087-2097. DOI: 10.1038/
mt.2012.144
[111] Kasza Z, Fredlund Fuchs P, 
Tamm C, Eriksson AS, O'Callaghan 
P, Heindryckx F, et al. MicroRNA-24 
suppression of N-deacetylase/N-
sulfotransferase-1 (NDST1) reduces 
endothelial cell responsiveness to 
vascular endothelial growth factor A 
(VEGFA). The Journal of Biological 
Chemistry. 2013;288:25956-25963. DOI: 
10.1074/jbc.M113.484360
[112] Chan MC, Hilyard AC, Wu C, Davis 
BN, Hill NS, Lal A, et al. Molecular basis 
for antagonism between PDGF and the 
TGFbeta family of signalling pathways 
by control of miR-24 expression. The 
EMBO Journal. 2010;29:559-573. DOI: 
10.1038/emboj.2009.370
[113] Zhou Q, Anderson C, Zhang H, Li 
X, Inglis F, Jayagopal A, et al. Repression 
of choroidal neovascularization 
through actin cytoskeleton pathways 
by microRNA-24. Molecular Therapy. 
2014;22:378-389. DOI: 10.1038/
mt.2013.243
[114] Jeggo PA, Lobrich M. Contribution 
of DNA repair and cell cycle checkpoint 
arrest to the maintenance of genomic 
stability. DNA Repair (Amst). 
2006;5:1192-1198. DOI: 10.1016/j.
dnarep.2006.05.011
[115] Qin G, Kishore R, Dolan CM, Silver 
M, Wecker A, Luedemann CN,  
et al. Cell cycle regulator E2F1 
modulates angiogenesis via p53-
dependent transcriptional control of 
VEGF. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2006;103:11015-
11020. DOI: 10.1073/pnas.0509533103
[116] Herbert SP, Odell AF, 
Ponnambalam S, Walker JH. Activation 
of cytosolic phospholipase A2-{alpha} 
as a novel mechanism regulating 
endothelial cell cycle progression and 
angiogenesis. The Journal of Biological 
Chemistry. 2009;284:5784-5796. DOI: 
10.1074/jbc.M807282200
[117] Ingber DE, Prusty D, Sun Z, 
Betensky H, Wang N. Cell shape, 
cytoskeletal mechanics, and cell cycle 
29
Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
DOI: http://dx.doi.org/10.5772/intechopen.82034
control in angiogenesis. Journal of 
Biomechanics. 1995;28:1471-1484. DOI: 
10.1016/0021-9290(95)00095-X
[118] Gillardon F, Moll I, Meyer M, 
Michaelidis TM. Alterations in cell 
death and cell cycle progression 
in the UV-irradiated epidermis of 
bcl-2-deficient mice. Cell Death and 
Differentiation. 1999;6:55-60. DOI: 
10.1038/sj.cdd.4400455
[119] Ashimori N, Zeitlin BD, Zhang Z, 
Warner K, Turkienicz IM, Spalding AC, 
et al. TW-37, a small-molecule inhibitor 
of Bcl-2, mediates S-phase cell cycle 
arrest and suppresses head and neck 
tumor angiogenesis. Molecular Cancer 
Therapeutics. 2009;8:893-903. DOI: 
10.1158/1535-7163.MCT-08-1078
[120] Diaz G, Engle RE, Tice A, 
Melis M, Montenegro S, Rodriguez-
Canales J, et al. Molecular signature 
and mechanisms of hepatitis D 
virus-associated hepatocellular 
carcinoma. Molecular Cancer Research. 
2018;16:1406-1419. DOI: 10.1158/1541-
7786.MCR-18-0012
[121] Zhou ZQ, Zhao JJ, Chen CL, 
Liu Y, Zeng JX, Wu ZR, et al. HUS1 
checkpoint clamp component (HUS1) is 
a potential tumor suppressor in primary 
hepatocellular carcinoma. Molecular 
Carcinogenesis. 2018. DOI: 10.1002/
mc.22908 [Ahead of print]
[122] Broustas CG, Hopkins KM, Panigrahi 
SK, Wang L, Virk RK, Lieberman 
HB. RAD9A promotes metastatic 
phenotypes through transcriptional 
regulation of anterior gradient 2 (AGR2). 
Carcinogenesis. 2018. DOI: 10.1093/
carcin/bgy131 [Ahead of print]
[123] Chen Q, Wang L, Jiang M, Huang 
J, Jiang Z, Feng H, et al. E2F1 interactive 
with BRCA1 pathway induces HCC two 
different small molecule metabolism or 
cell cycle regulation via mitochondrion 
or CD4+T to cytosol. Journal of Cellular 
Physiology. 2018;233:1213-1221. DOI: 
10.1002/jcp.25988
[124] Gramantieri L, Chieco P, 
Giovannini C, Lacchini M, Trere 
D, Grazi GL, et al. GADD45-
alpha expression in cirrhosis and 
hepatocellular carcinoma: Relationship 
with DNA repair and proliferation. 
Human Pathology. 2005;36:1154-1162. 
DOI: 10.1016/j.humpath.2005.07.017
[125] Majano PL, Garcia-Monzon 
C, Lopez-Cabrera M, Lara-Pezzi E, 
Fernandez-Ruiz E, Garcia-Iglesias C, 
et al. Inducible nitric oxide synthase 
expression in chronic viral hepatitis. 
Evidence for a virus-induced gene 
upregulation. The Journal of Clinical 
Investigation. 1998;101:1343-1352. DOI: 
10.1172/JCI774
[126] Shimoda K, Mori M, Shibuta K,  
Banner BF, Barnard GF. Vascular 
endothelial growth factor/vascular 
permeability factor mRNA expression 
in patients with chronic hepatitis C and 
hepatocellular carcinoma. International 
Journal of Oncology. 1999;14:353-359. 
DOI: 10.3892/ijo.14.2.353
[127] Si M, Lang J. The roles of 
metallothioneins in carcinogenesis. 
Journal of Hematology & Oncology. 
2018;11:107. DOI: 10.1186/
s13045-018-0645-x
[128] Lezina L, Spriggs RV, Beck D, Jones 
C, Dudek KM, Bzura A, et al. CD40L/
IL-4-stimulated CLL demonstrates 
variation in translational regulation 
of DNA damage response genes 
including ATM. Blood Advances. 
2018;2:1869-1881. DOI: 10.1182/
bloodadvances.2017015560
[129] Tehrani SS, Karimian A, Parsian 
H, Majidinia M, Yousefi B. Multiple 
functions of long non-coding RNAs in 
oxidative stress, DNA damage response 
and cancer progression. Journal of 
Cellular Biochemistry. 2018;119:223-
236. DOI: 10.1002/jcb.26217
